insulin glp-1 Frontiers JCI Insight - GLP-1 receptor

For MASH and liver disease Survodutide has Phase 2 data published in the NEJM showing 62% MASH resolution at the 4.8 mg dose, 62% liver fat reduction at the 6.0 mg dose, and meaningful fibrosis improvement

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management, with some now also licensed for weight management

Ongoing use can help sustain weight loss and support metabolic health, provided any side effects are properly managed with professional guidance

Choosing a GLP-1 for weight loss is a significant medical decision that requires balancing clinical effectiveness, personal lifestyle, and medical history

Only cautiously

How Might GLP-1s Improve Pregnancy Outcomes